Agrow is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


EFSA rejects another challenge to GM crop approvals

The European Food Safety Authority (EFSA) has rejected another complaint by anti-genetically modified crop groups against its positive risk assessments of three GM soybean lines. GeneWatch UK and TestBiotech challenged the European Commission’s import approvals of Monsanto’s glyphosate-tolerant and high oleic acid Vistive Gold (MON87705) and its stearidonic acid-improved MON87769, and DuPont’s acetolactate synthase herbicide-tolerant and high oleic acid Optimum GAT (305423). They argued that the approvals should be withdrawn because of the lack of specific guidance for assessing GM crops with significantly altered nutrient composition. The EFSA considers that the nutritional issues raised by the GM lines do not differ in principle from those arising from non-GM novel foods and ingredients. It concludes that the groups did not put forward new information that would invalidate the existing assessments. The EFSA recently rejected a complaint by TestBiotech against the import approval of Monsanto’s glyphosate-tolerant TruFlex Roundup Ready (MON88302) oilseed rape.



What to read next




Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts